Nancy Chan

Western University — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index2.0kcitations115works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fibroblast Growth Factor Research(22), Medical Imaging and Pathology Studies(17), Cancer Treatment and Pharmacology(16), HER2/EGFR in Cancer Research(14), Advanced Breast Cancer Therapies(13)

Publications114 total

Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021
npj Breast Cancer·2025· 1 citedOpen Access
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials
npj Breast Cancer·2025Open Access
Abstract P2-08-09: Predictors of inadequate ovarian function suppression (OFS) in premenopausal women with hormone receptor (HR)-positive breast cancer receiving a gonadotropin-releasing hormone (GnRH) agonist in combination with endocrine therapy
Clinical Cancer Research·2025
Abstract P2-07-21: A phase II study of pembrolizumab plus fulvestrant in ER positive, HER2 negative advanced/metastatic breast cancer patients
Clinical Cancer Research·2025· 1 cited
Abstract PS7-07: Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC)
Clinical Cancer Research·2025· 1 cited
Abstract P2-06-21: Preliminary validation of a multi-modal AI for stratification of early-stage breast cancer patients utilizing a foundation model for digital pathology
Clinical Cancer Research·2025· 1 cited
Abstract PS7-06: Elacestrant combinations in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase 1b/2, open-label, umbrella study
Clinical Cancer Research·2025
Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts.
Journal of Clinical Oncology·2025· 1 cited
Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.
Journal of Clinical Oncology·2025
Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
Journal of Clinical Oncology·2025· 1 cited
Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
Journal of Clinical Oncology·2025· 1 cited
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
UNC Libraries·2025Open Access
Acute kidney injury with cast nephropathy following creatine loading in a 17-year-old
Pediatric Nephrology·2025· 1 cited
Abstract LB413: Analysis of multimodal real world data from 1,248 breast cancer patients reveals distinct, novel consensus molecular segments associated with CDK4/6 inhibitor resistance
Cancer Research·2025
Acute Kidney Injury with Cast Nephropathy Following Creatine Loading in a 17-Year-Old: A Pediatric Case Report
2025Open Access
The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and Its Use in the Treatment of Breast Cancer
AAPS advances in the pharmaceutical sciences series·2025
Supplementary Table S9 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024Open Access
Supplementary Table S4 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024Open Access
Supplementary Figure S2 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024Open Access
Supplementary Table S12 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Jyoti Malhotra(11), Ann W. Silk(10), Janice M. Mehnert(10), Mark N. Stein(9), Joseph Aisner(8), Shridar Ganesan(7), Tracie Saunders(6), Bruce G. Haffty(6), Eugenia Girda(5), Joshua E. Allen(5), Tina Mayer(4), Kristen Spencer(4), Josep Tabernero(4), Joseph R. Bertino(4), Andrew Zloza(4), Deborah Toppmeyer(4), Shicha Kumar(4), Gregory Riedlinger(3), Roman Groisberg(3), Rastislav Bahleda(3)